Senecavirus

Seneca Therapeutics, Inc. Announces Issued U.S Patents for Tumor Endothelial Marker 8 (TEM8) Technology to Enable Better Patient Selection for SVV-001 Therapy

Retrieved on: 
Tuesday, August 24, 2021
Research, FDA, Genetics, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Cancer, ANTXR1, Genome, Memorial Sloan Kettering Cancer Center, Senecavirus, Method, SVV, Research, Patent, Therapy, United States patent law, 1836 U.S. Patent Office fire, Forward-looking statement, MSK, Patient, Invention, Pharmaceutical industry, Vaccine

TEM8 may enable pre-screening of solid tumors to determine if SVV-001 might be effective in that patient.

Key Points: 
  • TEM8 may enable pre-screening of solid tumors to determine if SVV-001 might be effective in that patient.
  • 11,096,972 B2 for Seneca valley virus (SVV) cellular receptor targeted oncotherapy, was issued today by the U.S. Patent Office.
  • Our exclusive license to these patents, with rights to sublicense, will help to maintain Seneca Therapeutics leadership in treating cancers using SVV.
  • Memorial Sloan Kettering (MSK) has intellectual property and associated interests related to Seneca by virtue of the licensing agreement between MSK and Seneca.

Oncorus Reports Second Quarter 2021 Financial Results and Provides Business Highlights

Retrieved on: 
Wednesday, August 4, 2021

Oncorus anticipates reporting initial interim data from the Phase 1 trial in the fourth quarter of 2021.

Key Points: 
  • Oncorus anticipates reporting initial interim data from the Phase 1 trial in the fourth quarter of 2021.
  • Oncorus expanded its Board with the appointments of Eric H. Rubin, M.D., and Barbara Yanni, in June 2021 and July 2021, respectively.
  • Research and development expenses for the quarter ended June 30, 2021 were $10.7 million compared to $6.7 million for the corresponding quarter in 2020.
  • General and administrative expenses for the quarter ended June 30, 2021 were $4.9 million compared to $2.0 million for the corresponding quarter in 2020.

Oncorus Reports First Quarter 2021 Financial Results and Provides Business Highlights

Retrieved on: 
Tuesday, May 4, 2021
Clinical medicine, Medicine, Virotherapy, Health sciences, Lipids, Oncolytic virus, Solid lipid nanoparticle, Coxsackievirus, Virus, Senecavirus, Immunotherapy

We also anticipate nominating our first two synthetic viral RNA (vRNA) immunotherapy candidates in the first half of 2021.

Key Points: 
  • We also anticipate nominating our first two synthetic viral RNA (vRNA) immunotherapy candidates in the first half of 2021.
  • These candidates are comprised of vRNA coding for oncolytic viruses encapsulated within lipid nanoparticles, or LNPs \xe2\x80\x93 proprietary technologies developed by the Oncorus team.
  • Oncorus continues to advance its lead synthetic, IV administered vRNA immunotherapy programs based on the Coxsackievirus A21 (CVA21) and the Seneca Valley Virus (SVV).
  • In January 2021, Oncorus announced the signing of a 15-year lease to build a state-of-the-art, 88,000 square foot GMP viral immunotherapy clinical manufacturing facility in Andover, Mass.

Seneca Therapeutics Announces Acceptance of Late Breaking SVV-001 Abstract to American Association for Cancer Research Annual Meeting April 10-15, 2021

Retrieved on: 
Monday, March 15, 2021
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Life sciences, Biotechnology, Biology, Virotherapy, Pharmaceutical industry, Pharmacy, Specialty drugs, Senecavirus, Oncolytic virus, SVV, Biopharmaceutical, Seneca people

Seneca Therapeutics, Inc. (STI), a clinical-stage biopharmaceutical company dedicated to the development of targeted oncolytic immunotherapeutics based on Seneca Valley Virus (SVV-001) announced today the acceptance of a late breaking SVV-001 abstract to the American Association for Cancer Research annual meeting.

Key Points: 
  • Seneca Therapeutics, Inc. (STI), a clinical-stage biopharmaceutical company dedicated to the development of targeted oncolytic immunotherapeutics based on Seneca Valley Virus (SVV-001) announced today the acceptance of a late breaking SVV-001 abstract to the American Association for Cancer Research annual meeting.
  • The details of the abstract viewing are below:
    Seneca Therapeutics was founded by Dr. Paul Hallenbeck to develop SVV-001 related products.
  • Seneca Therapeutics is also developing armed versions of SVV-001 to selectively express gene product(s) that are inserted into the genome of SVV-001 and create additional anti-tumor effects.
  • This press release contains forward-looking statements concerning the development of Seneca Therapeutics products, the potential benefits and attributes of those products, and the companys expectations regarding its prospects.